4-Prop-1-en-2-ylheptan-4-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-Prop-1-en-2-ylheptan-4-amine
• 英文别名: 4-prop-1-en-2-ylheptan-4-amine
• 化学式: C₁₀H₂₁N
• 分子量: 155.28
• InChiKey: MWWNLSHKQUSAHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Chongqing Upgra Biological Sci.&Tech., Ltd.

  公开号：EP3677284A1

  公开（公告）日：2020-07-08

  Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.

  本发明公开了一种具有协同抗癌活性的中间体药物和一种聚乙二醇偶联协同抗癌药物，以及其制备方法和用途。中间体药物的结构通式为（I），聚乙二醇偶联增效抗癌药物的结构通式为（II）。该药物实现了多种抗癌药物的联合用药，避免了服用多种抗癌药物时因药物间相互作用或药物药代动力学引起的毒性反应，有利于克服癌症的多药耐药性，具有协同增效作用，可用于制备抗癌药物和治疗癌症。